Go Deep
Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 22,033 | -1.7 | 0.78 | 0.00 | 190.38 |
| Oct 2026 | 22,057 | -1.7 | 0.77 | 0.00 | 188.48 |
| Oct 2026 | 22,129 | -1.7 | 0.74 | 0.00 | 183.00 |
| Oct 2026 | 22,045 | -1.7 | 0.77 | 0.00 | 189.63 |
| Oct 2026 | 22,021 | -1.8 | 0.78 | 0.00 | 191.06 |
| Oct 2026 | 22,129 | -1.7 | 0.74 | 0.00 | 182.17 |
Xenetic Biosciences, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 660,601.0 | 806,923.0 | 766,296.0 | 1,026,957.0 |
| Net Profit | -929,695.0 | -456,382.0 | -579,076.0 | -509,940.0 |
| EPS | -0.4 | -0.2 | — | -0.3 |
Xenetic Biosciences, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 2,976,411.0 | 2,500,284.0 | 2,539,986.0 | 1,706,925.0 | — |
| Net Profit | -2,680,860.0 | -3,960,275.0 | -4,134,578.0 | -6,552,353.0 | — |
| EPS | -1.6 | -2.6 | -2.7 | -4.6 | — |
Xenetic Biosciences, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 8,363,847.0 | 6,901,443.0 | 10,605,226.0 | 14,720,290.0 | — |
| Total Liabilities | 968,025.0 | 894,263.0 | 809,585.0 | 1,073,156.0 | — |
| Total Equity | 7,395,822.0 | 6,007,180.0 | 9,795,641.0 | 13,647,134.0 | — |
Owes vs Owns
Xenetic Biosciences, Inc. owed $0.13 for every $1 it owned in Jun 2026, up from $0.07 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.13× | 0.12× | 0.13× | 0.08× | 0.07× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Xenetic Biosciences, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 94.3%Other assets 5.7%
How it's funded — Dec 2025
Payables 3.1%Other liabilities 8.5%Shareholders' equity 88.4%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 7.9 | 6.2 | 9.0 | 13.1 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.0 | 0.0 | 0.0 | 0.0 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 0.5 | 0.7 | 1.6 | 1.6 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Payables | 0.3 | 0.3 | 0.2 | 0.3 |
| Other liabilities | 0.7 | 0.6 | 0.6 | 0.8 |
| Shareholders' equity | 7.4 | 6.0 | 9.8 | 13.6 |
| Net tangible assets | 7.4 | 6.0 | 9.8 | 13.6 |
Xenetic Biosciences, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -2,286,651.0 | -2,817,478.0 | -4,114,219.0 | -4,646,765.0 | — |
| Investing Activities | — | — | 0.0 | -500,000.0 | 0.0 |
| Financing Activities | 4,004,715.0 | 0.0 | — | 0.0 | 11,454,545.0 |